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Antimicrobial resistance is a global health crisis and few novel antimicrobials have been
discovered in recent decades. Natural products, particularly from Streptomyces, are the source
of most antimicrobials, yet discovery campaigns focusing on Streptomyces from the soil
largely rediscover known compounds. Investigation of understudied and symbiotic sources
has seen some success, yet no studies have systematically explored microbiomes for anti-
microbials. Here we assess the distinct evolutionary lineages of Streptomyces from insect
microbiomes as a source of new antimicrobials through large-scale isolations, bioactivity
assays, genomics, metabolomics, and in vivo infection models. Insect-associated Streptomyces
inhibit antimicrobial-resistant pathogens more than soil Streptomyces. Genomics and meta-
bolomics reveal their diverse biosynthetic capabilities. Further, we describe cyphomycin,
a new molecule active against multidrug resistant fungal pathogens. The evolutionary
trajectories of Streptomyces from the insect microbiome influence their biosynthetic potential
and ability to inhibit resistant pathogens, supporting the promise of this source in augmenting
future antimicrobial discovery.
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The rapid emergence of antimicrobial resistance in bacterialand fungal pathogens is a public health crisis1,2. Noveltherapeutics are needed to counter resistance, yet no new
antimicrobial classes have been clinically approved in over three
decades3. Natural products are the main source of antimicrobials,
the majority of which are produced by Actinobacteria cultured
from the soil3,4. However, contemporary studies of this once
prolific source of novel chemistry face dramatically diminishing
returns, largely due to the rediscovery of known compounds5.
Efforts to address this issue, including genome mining6,7, syn-
thetic biology8, and exploring alternative microbial sources, such
as marine microbial environments9–12 and underrepresented
taxa13,14, have yielded limited success. To combat the continual
emergence of multidrug-resistant pathogens, there is a critical
and constant need to discover new antimicrobial natural
products.
Natural products are the language of microbial interactions,
evolved to mediate communication and antagonism among
and between species15,16. Within microbiomes, the ecology and
diversity of natural product chemistry reflect the underlying
interactions between the microbial community, host, and
environment. Exploration of the specialized natural product
chemistry embedded within host microbiomes is an emerging
new paradigm in antimicrobial drug discovery. Antimicrobials
have recently been discovered from the microbiomes of diverse
eukaryotic hosts, ranging from sea squirts17 to humans18. A
particularly compelling source of novel antimicrobials lies in
defensive symbioses, where bacterial symbionts produce anti-
microbials to protect against opportunistic and specialized
pathogens19–23. In insects, these symbioses are best exemplified in
fungus-growing ant19–21, solitary digger wasp22, and southern
pine beetle23 (Fig. 1a, right) systems, where Actinobacteria
(typically Streptomyces) provide chemical defenses, paralleling
our own reliance on the antimicrobials produced by these taxa to
combat infectious disease. For example, the Streptomyces sym-
biotically associated with the southern pine beetle (Dendroctonus
frontalis) produce the secondary metabolites frontalamide A,
frontalamide B, and mycangimycin23,24. Mycangimycin inhibits
the beetles’ antagonistic fungus Ophiostoma minus and has potent
inhibitory activity against malaria while the frontalamides have
general antifungal activity23,24. Solitary wasps also associate with
Streptomyces that provide antibacterial and antifungal chemical
protection to their larvae through production of streptochlorin, a
variety of piericidin analogs, and other molecules25. The anti-
fungal compound sceliphrolactam was discovered from Strepto-
myces associated with a mud dauber wasp25. The natalamycin
derivatives produced by Streptomyces from the fungus-growing
termite system provide similar antifungal defense26. Further, over
10 new natural products with antimicrobial activity have been
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Fig. 1 Sampling strategy for Streptomyces from insect microbiomes. Streptomyces were isolated from a wide range of insects and geographies (1445 insects;
10,178 strains; dot size, insects sampled). Streptomyces production of the antifungal mycangimycin (1) in the Southern Pine Beetle system is shown at right.
Cyphomycin (2) is a new antifungal described herein. Photo credits: southern pine beetle - Erich G. Vallery; fungus-growing ant – Alexander Wild
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100 insect-Streptomyces strains23,24,27,28. Globally there are over
five million insect species that occupy virtually every terrestrial
niche29. Although insects are among the most diverse organisms
on the planet29, studies of Actinobacteria from these systems have
been limited to only a few insect orders, specifically Hymenoptera
and Coleoptera. Further, insects themselves exhibit complex
chemistry that mediates and maintains the diversity of their
ecological interactions30.
Here, we systematically examine our hypothesis that insect
microbiomes are a valuable source of new antimicrobials. The
extreme diversity of insects presents untapped potential for drug
discovery from their equally diverse microbial communities.
However, the breadth of natural product biosynthesis and anti-
microbial potential within insect microbiomes remains relatively
unknown. We hypothesize that Streptomyces from insect micro-
biomes represent a promising source of antimicrobials with dis-
tinct evolutionary histories from soil Streptomyces, upon which
most antimicrobial discovery efforts have focused. We focus on
Streptomyces because this genus: (i) is the source of most clinically
used antibacterials and antifungals, (ii) has established genetic
tools to facilitate development8, and (iii) has been implicated in
readily forming associations with diverse insect hosts31.
Results
Streptomyces are commonly found in insect microbiomes.
Counter to the prevailing assumption of Streptomyces being lar-
gely soil-associated bacteria, in our shotgun metagenome ana-
lyses, Streptomyces comparably occur in host-associated and soil-
associated contexts. Specifically, we calculate the number of
Streptomyces reads per megabase (rpM) to be 129.32 rpM and
172.72 rpM for host-associated and soil studies, respectively (data
from ref. 4). Metagenomes from freshwater (47.49 rpM) and
marine (24.65 rpM) sources are much lower in Streptomyces
abundance and support the hypothesis that most Streptomyces are
either soil- or host-associated.
Focusing on insect hosts, we first determined that associations
between Streptomyces and insects are widespread through
sampling 2561 insects spanning 15 taxonomic orders (Fig. 1,
host donut chart, and Supplementary Data 1) and a wide range of
geographies and biomes (Fig. 1, map and biome donut chart).
Actinobacteria were isolated from 1445 of 2580 insect micro-
biomes (56%) spanning 13 orders, resulting in 10,178 individual
isolates, including 2934 from Hymenoptera, 2920 from Diptera,
1326 from Lepidoptera, and 1139 from Coleoptera (Supplemen-
tary Data 2). Additionally, 6935 isolates were obtained from other
sources (soil: n= 833; plants: n= 980). Phylogenetic placement
of 536 insect-associated and 571 free-living strains indicates that
specific lineages of Streptomyces are enriched for associations with
insects (Fig. 2).
Insect-Streptomyces exhibit high inhibitory activity. Through
51,050 individual antimicrobial bioactivity assays, pairing 2003
Streptomyces strains against a panel of 27 clinically and/or eco-
logically relevant microbes (Supplementary Data 3), we show that
insect-associated strains (n= 1162) exhibited significantly greater
inhibitory activity towards fungi, Gram-negative bacteria, and
Gram-positive bacteria, compared to both soil (n= 186) and
plant-associated (n= 178) Streptomyces isolates (Fig. 3a–c, Sup-
plementary Figure 1A, and Supplementary Data 4). Specifically,
insect Streptomyces strains had significantly greater antifungal
activity, as indicated by inhibition fractions, the fraction of fungi
for which a strain exhibited antimicrobial inhibition, where
average inhibition fractions for insect-Streptomyces were 0.52 ±
0.01 fraction inhibition compared to 0.42 ± 0.02 (p= 9.46e−3; t-
test, BY correction) and 0.36 ± 0.03 (p= 7.84e−7; t-test, BY
correction) for soil and plant-associated strains, respectively
(Fig. 3a). Against Gram-negative bacteria, insect-associated
strains had an inhibition fraction of 0.26 ± 0.01 compared to
0.17 ± 0.02 (p= 6.45e−4; t-test, BY correction) and 0.12 ± 0.02
(p= 2.07e−7; t-test, BY correction) for soil and plant-associated
Streptomyces, respectively (Fig. 3b). Against Gram-positive bac-
teria, insect-associated strains had an inhibition fraction of 0.61 ±
0.01 compared to 0.45 ± 0.02 (p= 7.84e—7; t-test, BY correction)
and 0.34 ± 0.03 (p= 7.06e−16; t-test, BY correction) for soil and
plant-associated strains, respectively (Supplementary Figure 1A).
Some insect host orders associate with Streptomyces with espe-



















































S. xinghaiensis NRRL B-24674 SID5475
S. sp. M56 SID8382
S. sp. M27 SID8361
S. sp. MspMP-M5 SID8354
S. celluloflavus NRRL B-2493 SID7805
S. sp. ScaeMP-e96 SID4951
S. sp. ISID311
S. sp. FxanaC1 SID8375
S. sp. SID7834
S. sp. PalvLS-984 SID4941
S. sp. OspMP-M45 SID4925
S. sp. DpondAA-B6 SID4912
S. sp. DpondAA-F4a SID4940
S. sp. DpondAA-F4a SID4939
S. sp. DpondAA-A50 SID8360
S. sp. DvalAA-83 SID8357
S. sp. SirexAA-E SID1
S. sp. ScaeMP-e122 SID8358
S. sp. ScaeMP-e83 SID4937
S. sp. AmelKG-AP SID8374
S. sp. SID2119
S. sp. ScaeMP-e10 SID5594
S. sp. Wigar10 SID4944
S. sp. CcalMP-8W SID8356
S. sp. SolWspMP-sol2th SID8359
S. sp. AmelKG-D3 SID8350
S. sp. SA3 actG SID4926
S. sp. HrubLS-53 SID8380
S. sp. LcepLS SID4945
S. sp. ScaeMP-6W SID4934
S. sp. LaPpAH-201 SID8370
S. sp. LaPpAH-202 SID8371
S. sp. BvitLS-983 SID4915









S. coelicoflavus ZG0656 SID5477
S. coelicolor A3-2 SID7813
S. sp. FxanaD5 SID8376
S. sp. AmelKG-F2B SID8352
S. chartreusis NRRL 12338 SID5464
S. virens NRRL B-24331 SID7804
S. albus J1074 SID7817
S. sp. SID3915
S. sp. LamerLS-31b SID4921
S. flavogriseus ATCC 33331 SID7815
S. rimosus ATCC 10970 SID5471
Fig. 2 Distinct lineages of Streptomyces associate with insect hosts. a A
genomic phylogeny constructed from 93 single-copy core bacterial genes is
shown to the left with the major clades, Clade I (C–I) and Clade II (C-II),
labeled (B= Basal, S= Streptomyces). 16S sequences were mapped to the
genomic phylogeny and the distribution of free-living (tan) and insect-
associated (blue) strains is shown as both pie and bar charts to the right.
Number of total strains is shown to left of pies. b–f A more detailed
mapping of 16S sequences onto the genomic tree is shown for clades S01
(b), S06 (c), S07 (d), S08 (e), and S13 (f). g–j 16S phylogenies from
sequences mapped to clade S06 (g), S07 (h), S08 (i), and S13 (j)
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(Fig. 3c). For example, strains isolated from Orthoptera (crickets
and grasshoppers; n= 39), Blattodea (termites and cockroaches;
n= 87), and Hymenoptera (ants, bees, and wasps; n= 518) had
particularly high inhibition against Gram-negative bacteria and
had inhibition fractions of 0.25, 0.16, 0.11 higher than the average
soil isolate, respectively. In challenges against fungi, strains from
Blattodea (termites and cockroaches; n= 87) and Lepidoptera
(moths and butterflies; n= 94) had particularly effective anti-
microbial activity, with inhibition fractions greater than that of
the average soil isolate by 0.26 and 0.13, respectively. Similar
trends were seen in Gram-positive assays (Supplementary
Figure 1B).
Insect-associated strains have higher bioactivity against these
pathogen classes compared to soil Actinobacteria (Fig. 3a–c,
Supplementary Figure 1A-B) and variation of activity between
host orders suggests the microbiomes of some insect lineages are
better equipped to defend against specific pathogen classes
(Fig. 3c, Supplementary Figure 1D-E). Furthermore, insect-
associated Streptomyces generally have higher rates of inhibition
(i.e., hit rate) against many important clinical pathogens,
including Pseudomonas aeruginosa, Acinetobacter baumannii,
Candida albicans, and methicillin-resistant Staphylococcus aureus
(Fig. 3d). These assays reflect traditional, albeit high-throughput,
approaches for antimicrobial screening. Biosynthesis of secondary
metabolites is often dependent on many factors not present in the
lab, so metabolites from certain environments (e.g., a host-
associated Streptomyces cultured in the absence of environmental





































































































































































































































































































































































































Fig. 3 Bioactivity of insect-associated Streptomyces. a Fungal and b Gram-negative pathogens are significantly more inhibited by insect-associated isolates
compared to soil- and plant-sourced Streptomyces (n= 1162, 186, and 178 for insect, soil, and plant, respectively; ***p < 1e−3; **p < 1e−2; t-test, BY
correction). c Strains vary in antimicrobial bioactivity by insect host orders (n= 87, 69, 327, 518, 94, and 39 for Blattodea, Coleoptera, Diptera,
Hymenoptera, Lepidoptera, and Orthoptera, respectively). a–c: center, median; box, upper and lower quantiles; notches, 95% confidence; whiskers, 1.5×
interquartile range; points, outliers. d Hit rate for insect, soil, and plant strains against individual pathogens (n= 1162, 186, and 178 for insect, soil, and plant,
respectively)
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Nevertheless, significantly higher overall inhibitory activity of
insect Streptomyces compared to soil strains suggests insects
generally associate with strains with greater antimicrobial
potential and thus represent a promising source for antimicrobial
discovery.
Biosynthetic potential is shaped by ecology and phylogeny. We
next determined the genomic potential of insect-associated
Streptomyces as a source of novel natural products. Core-
genome phylogenetic studies of 120 strains (69 from insects)
show that specific lineages of Streptomyces appear to be associated
with insect hosts. Most insect-associated Streptomyces strains
cluster together in discrete insect-associated lineages, often
separated from soil Streptomyces lineages by millions of years34.
This is further supported by our 16S rRNA gene phylogeny
(Fig. 2). Thus, our findings suggest that Streptomyces from insects
occupy unique evolutionary space for natural product discovery
(Supplementary Figure 2A, subset shown in Fig. 4a). Through
identification and characterization of the 4948 biosynthetic gene
cluster (BGC) fragments present in these genomes via anti-
SMASH35, we show insect-associated Streptomyces harbor vast
potential for natural product biosynthesis. BGCs were classified
into 2672 families with BiG-SCAP36 over 71% of which were
present within only a single genome (Supplementary Figure 2B,
Supplementary Data 5). Among BGCs, 31% (1539) were flanked
by at least 0.5 kb of sequence on either side, indicating the BGC
was fully resolved. Notably, the distinct evolutionary lineages of
Streptomyces enriched in insect-associated strains harbor much of
the uncharacterized biosynthetic potential and have led to the
discovery of new molecules (such as cyphomycin; see Fig. 5). Soil
and insect Streptomyces had similar full-length BGC abundances
in major biosynthetic cluster types and dedicated similar fractions
of their genomes to secondary metabolism (11% and 12%,
respectively; Supplementary Figure 2C-E). Uncharacterized BGCs
are abundant across Streptomyces. Known BGCs are primarily
found within well-studied, soil-derived species such as S. griseus
and S. coelicolor, which may contribute to the issue of compound
rediscovery during soil-centered sampling campaigns. The
diversity of BGCs with respect to both sub-clade (Fig. 4a, phy-
logeny) and source indicates that the BGCs present within a
Streptomyces genome are influenced by both phylogeny and
ecology (Fig. 4b). Many BGC families had a Shannon entropy of
zero with respect to their sub-clade, indicating their strong phy-
logenetic signal is likely related to a vertical evolutionary history.
Other BGC families were source invariant, indicating that they
are found exclusively within a specific ecological context (e.g.,
only within insect microbiomes). The influence of both phylo-
geny and ecology on BGC content further supports that Strep-

























































































































































































































































































































































































































































































































































































































































































































































Fig. 4 Ecology and phylogeny influence biosynthetic potential. a A core-genome phylogeny shows evolutionarily distinct lineages of Streptomyces associate
with insects (subset shown, see Supplementary Figure 2). BGC similarity to known BGCs highlights the biosynthetic diversity of insect microbiome strains.
b Source invariant (blue) and sub-clade invariant (red) BGC families suggest BGC presence is influenced by both source and phylogeny. LC/MS
metabolomics revealed MFs that are unique to c source and d phylogeny. e PCA of the metabolomes identified an outlier strain and f MFs that contribute
to its uniqueness, including cyphomycin
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Ecology and phylogeny influence metabolomic profiles. We
also compared the chemical fingerprints of insect-, plant-, and
soil-sourced Streptomyces using untargeted liquid chromato-
graphy mass spectrometry (LC/MS) metabolomics of 120 strains
(69 from insects, same strains as in genomics above). In accor-
dance with genomic predictions of chemical diversity from BGCs,
molecular features (MFs) from LC/MS support that metabolome
chemical diversity is also heavily influenced by both phylogeny
and ecology. Here, our detection of 7727 unique but reproducible
(present in all three replicates, but in only 1 of the 120 strains
examined) MFs, suggests substantial and specialized chemical
diversity in our sampling. Over 4500 (59%) of MFs were found to
be unique to a single strain and 80.2% were found in four or fewer
strains (Supplementary Figure 2F, Supplementary Data 6). Most
MFs (3244) are found solely in insect microbiomes within our
sampling and 1179 and 2325 are present only in the Clade I and
II evolutionary lineages34, respectively, further supporting the
influence of both source and phylogeny on chemical diversity
(Fig. 4c, d). Principal component analyses (PCA) of these meta-
bolomes identified a Streptomyces sp. ISID311 as metabolic out-
lier within a group of related Streptomyces (Fig. 4e). A loadings
analysis of these principal components identified MFs driving this
strain’s uniqueness, including the new antifungal cyphomycin
(Fig. 4f).
Insect-Streptomyces fractions have potent in vivo activity. To
validate that insect microbiomes represent a source of anti-
microbials with activity against human pathogens, we conducted
in vivo efficacy testing of chemical fractions obtained from dif-
ferent insect Streptomyces strains using murine models for
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Fig. 5 Insect-associated Streptomyces are a source of active antimicrobials. a Fractionated extracts from insect microbiomes are active in multiple murine
models of drug-resistant infection. Less infective burden is seen in intraperitoneally treated mice after 8 h of infection. Each dot represents a unique fraction
in one mouse study. (n= 15, 11, and 8 for C. albicans, E. coli, and P. aeruginosamodels, respectively; center, median; box, upper and lower quantiles; whiskers,
1.5× interquartile range. b Most fractions from insect microbiomes show no hemolysis in cell-based assays. Safe indicates no toxicity at >100×
concentration associated with efficacy. c The antifungal cyphomycin is produced by Streptomyces isolated from d the fungus-growing ant Cyphomyrmex sp.
Photo credit: Alexander Wild e Cyphomycin-containing fractions show potency against the ant pathogen Escovopsis sp. (top left, bottom). f Purified
cyphomycin exhibits potency against resistant pathogens. g Mouse candidiasis (C. albicans) models showcase reduced infection and a dose-like response
to cyphomycin. Dots indicate individual mice
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infections (n= 8, 11, and 15, respectively; Fig. 5a). Fractions with
in vitro activity were subsequently analyzed using UPLC-MS. On
average, fractions contained five or fewer compounds, which were
compared to Antibase37, a database comprised mostly of micro-
bial natural products. Fractions that contained m/z values indi-
cating the presence of unknown/novel molecules and the absence
of known molecules (within 5 parts per million) were used in
subsequent in vivo mouse studies. Mice treated with fractions
from insect-associated Streptomyces had a 1.32 and 0.77 log
reduction in infectious burden of the Gram-negative pathogens
P. aeruginosa or E. coli, respectively, compared to untreated
controls. Mice infected with the fungal pathogen C. albicans had a
1.07 log reduction in infectious burden when treated with insect-
Streptomyces fractions. Fractions from insect microbiome Strep-
tomyces show no toxicity in hemolysis assays (concentrations of
50–500 µg mL−1) for 42 of 46 fractions (91%; Fig. 5b).
Discovery of cyphomycin, a new antifungal compound. From
one such fraction that was positive in mouse studies, we describe
the new antifungal compound cyphomycin (Fig. 5c, Supple-
mentary Figures 3 and 4) from a Brazilian Streptomyces (ISID311)
isolated from the microbiome of the fungus-growing ant
Cyphomyrmex sp. (Fig. 5d). The cyphomycin type 1 polyketide
synthase BGC is 199 kb in length (Fig. 5c; polyketide open
reading frames shown in blue, tailoring genes in yellow). It has
biosynthetic similarity to the PM100117/8 family of antitumor
compounds38 (BiG-SCAPE distance of 0.278) and structural
similarity to the deplelides39, yet has key differences in the
macrolide core and glycosylation (Supplementary Figures 3 and
4). The Streptomyces that produce PM100117/8 and deplelide
have 99.04% and 98.6% 16S rRNA gene sequence similarity to
ISID311, respectively. The PM100117/8 producing Streptomyces
was isolated from a marine polychaete worm (genus Filograna)
indicating potential for invertebrate-specialized structures and
mechanisms in this class. Purified cyphomycin is active against
multidrug-resistant fungal infections both in vitro and in vivo
(Fig. 5e–g). Further, cyphomycin shows potent in vitro activity
against both the ecologically relevant fungus-growing ant
pathogen Escovopsis sp. (Fig. 5e) and the resistant human
pathogens Aspergillus fumigatus 11628 (triazole resistance), C.
glabrata 4720 (echinocandin resistance), and C. auris B11211
(echinocandin, triazole, and amphotericin B resistance), with low
minimum inhibitory concentrations (MICs) in vitro (Fig. 5f).
Activity against fungi with resistance mechanisms to all three
clinically used classes of antifungals indicates that further study
exploring cyphomycin’s mechanism of action and resistance is
warranted. In a neutropenic mouse disseminated candidiasis
model40, infective burden was 5.38 ± 0.04 log10 CFU per kidney
for fluconazole (4 mg kg−1), 5.2 ± 0.08 for amphotericin B (1 mg
kg−1), 4.8 ± 0.03 for micafungin (4 mg kg−1), and 6.78 ± 0.02 for
untreated controls (all n= 3). It is important to note that these
doses produce the same plasma drug exposure seen in humans
using standard dosing regimens41. In a single-dose study of
cyphomycin in the same model, cyphomycin exhibited an in vivo
dose–response with 0.56 and 0.66 log reduction of infectious
burden compared to the start of therapy when treated with 20 and
40 mg kg−1 cyphomycin, respectively (Fig. 5g), demonstrating
cyphomycin’s potential for treating clinically relevant pathogens
in this industry-standard model of Candida infection42.
Discussion
Through our systematic assessment, we show insect microbiomes
present a promising source of novel natural products. Our
application of genomics, metabolomics, and ecologically opti-
mized bioassays facilitates rapid screening of strains to explore
their untapped chemical diversity. Although primarily thought of
as soil microbes, we show Streptomyces from phylogenetically
distinct lineages commonly form associations with diverse insect
hosts. The unique chemical defenses of insect Streptomyces, such
as mycangimycin23 and sceliphrolactam27, and other insect-
associated Actinobacteria, such as dentigerumycin19 and selva-
micin21, have been a fruitful discovery resource in the recent past.
Inhibition of Gram-negative and fungal human pathogens
(Fig. 3a–c) highlights the value of insect-associated Streptomyces
as a source of bioactive molecules. Furthermore, these strains
exhibit higher levels of inhibition than strains isolated from tra-
ditional sources (i.e., soil) that primarily result in the rediscovery
of known compounds43. Genomic characterization of the bio-
synthetic potential of these strains and the metabolomic char-
acterization of their produced metabolites highlight the unique
chemical diversity of Streptomyces from insect microbiomes.
Cyphomycin is an example of new chemistry from this innovative
source. Importantly, the fractions discovered though in vitro and
in silico screening retain high efficacy in mouse models of
C. albicans, E. coli, and P. aeruginosa infections, and exhibit low
toxicity in hemolysis assays (Fig. 5a, b). The unique ecological
and evolutionary pressures on the chemical phenotypes of insect
microbiomes may have further application in conservation,
agriculture, and ecosystem health.
Insect microbiomes appear a particularly valuable source of
antimicrobials for treating fungal diseases. High mortality rates
and widespread emergence of resistance to many or all known
antifungals have made invasive fungal infections a worldwide
health burden44. The few effective antifungal therapeutics are
often plagued with high toxicity and off-target effects and have
done little to reduce the high mortality rates of multidrug-
resistant fungal disease44. Streptomyces from insect microbiomes
represent a prolific source of antifungal natural products and we
show that insect strains exhibit significantly greater activity
against fungi than soil Streptomyces (Fig. 3a). Further, we present
that cyphomycin, a new molecule isolated from a fungus-growing
ant microbiome, is active against multidrug resistant fungal
pathogens and demonstrates in vivo efficacy in a commonly
utilized infection model for PK/PD studies and FDA applications
(Fig. 5f, g). Compared to existing FDA-approved antifungal
agents, cyphomycin’s 0.25 µg mL−1 in vitro MIC against C.
albicans K1 is similar to both amphotericin B and fluconazole
(0.25 and 0.5 µg mL−1, respectively). It is important to note that
the deplelides are not described as antifungals, but rather anti-
tumor molecules. Further, we see no evidence of toxicity in mouse
studies of cyphomycin and animals exhibited no observed phy-
sical or behavioral changes, suggesting that the insect-Strepto-
myces cyphomycin is a more specific molecule than the soil-
derived deplelides that are generally toxic to eukaryotes. Together,
activity against multidrug-resistant fungi in vitro coupled with
high efficacy in in vivo mouse models of infection highlight
cyphomycin’s potential as a drug lead to treat multidrug resistant
fungal infections (Fig. 5f, g).
Antimicrobials developed from soil Streptomyces are the
foundation of modern medicine and have saved countless lives.
Widespread resistance to these compounds, in combination with
the apparent exhaustion of soil Streptomyces as a source of new
antimicrobials, represents an alarming health crisis—the rate of
antimicrobial resistance continues to far outpace the discovery
of novel antimicrobial natural products2,14,45. The promise of
insect-associated Streptomyces as a new source of antimicrobials
has the potential to reinvigorate the stagnated antibacterial and
antifungal discovery pipelines. This source has potential far-
reaching applications stemming from their ecological roles
mediating pathogen dynamics associated with their insect hosts.
Insects, through evolution, are predicted to have undergone
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millions of years of continual bioprospecting for active, defensive
molecules; pathogen pressure selects for association with Strep-
tomyces strains that produce efficacious antimicrobials. Further-
more, insect symbionts are uniquely suited to medicinal
discovery, as their host associations appear to enrich for com-
pounds with low toxicity to animals. Our validation of Strepto-
myces from insect microbiomes as a rich source of bioactive
natural products demonstrates the extensive opportunities for
antimicrobial discovery within the vast chemical diversity of these
microbial communities.
Methods
Host collection. Host-associated strains were obtained from seven field collections
(Florida, Hawaii, Alaska, New Mexico, Wisconsin, California, Brazil) from 2014 to
2016, with various Currie lab archival strains (Supplementary Data 1). Each host
was collected using sterile forceps and deposited into a pre-sterilized, pre-barcoded
container. Field collections focused heavily on insects that were not in direct
contact with soil to avoid the possibility of soil contamination in subsequent
surface isolation. Metadata recorded at each field site included: researcher infor-
mation, date, location, GPS coordinates, micro and macro environment, host
description, as well as photographs of each field-site. All specimens were assigned a
unique host-identification number (HID) and stored at 4 °C.
Processing and bacterial isolation. All hosts are photographed via dissecting
scope and cataloged by HID.
Insect specimens were processed based on host integrity. If the sample was large
enough and completely intact it was processed for external and internal microbial
isolates. Large samples were also processed by particle method, using a sterilized
surgical scalpel to remove portions of each specimen and placing each piece on an
agar plate. If small, degraded or compromised, samples were processed using a
combination method: the same procedure as the internal isolation without surface
sterilization. External isolation involves transferring host specimen into a 1.5 mL
microcentrifuge tube, adding 125*x (x= number of plates) µL phosphate-buffered
saline (PBS), vortexing gently at 50% speed for 10 s, and transferring 100 µL to
various media. To select for Actinobacteria, humic acid Agar (HV)46 and selective
chitin media47 with 20 mL/1 L nystatin, and 10 mL/1 L cycloheximide added to
select against fungal isolates were used. After plating for external isolates, a
sterilization wash is preformed to isolate internal microbes. The same
microcentrifuge tube from the external was filled with 1 mL of 70% ethanol and
gently mixed by inversion for 1 min. Ethanol waste was removed and 1 mL of 1%
bleach with 0.1% tween20 solution was added and mixed gently for 30 s by
inversion. Supernatant was removed and host specimen was rinsed 3× using 1 mL
PBS buffer for 10 s. After external sterilization, 125*x (x= number of plates) µL of
PBS was added to the tube. The specimen was then ground-up using a sterile pestle
inside the tube. Using a wide bore 200 µL tip, 100 µL of slurry was transferred onto
a pre-labeled media plate (HV & chitin) and spread evenly. The last 100 µL was
pipetted into a DNA voucher containing 900 µL of 95% ethanol for storage.
Plant tissue was vortexed in PBS and 100 µL plated. Remaining tissue was then
surface sterilized, crushed, and plated similarly. Particle plates were generated for
some plants, where we plant tissue was placed directly on plates. The same selective
protocols as above were used.
Soil was treated similarly by re-suspending 1 g into 1 mL of PBS, followed by a
1e−5 serial dilution on chitin and HV. Colonies were then picked.
For all sources, HV and chitin isolation plates were incubated aerobically at
room temperature (28 °C) and checked for bacterial growth at 14 d, 30 d, and 90 d.
Colonies exhibiting characteristic Actinobacterial morphology48 were assigned a
strain identification number before isolation onto fresh HV or chitin media and
incubation at 28 °C.
16S sequencing and phylogenetic placement. Genomic DNA was extracted from
isolates using the Powersoil DNA isolation kit according to manufacturer’s spe-
cifications (MoBio). Polymerase chain reaction (PCR) was performed using the
universal bacterial primer set 27 F (5′-AGA GTT TGA TCM TGG CTC AG-3′)
and 1496 R (5′-CGG TTA CCT TGT TAC GAC TT-3′), of hypervariable regions
V1-V9. PCR was performed in a standard 25 µL reaction with 1 µL DNA template
(20 ng µL−1), 12.5 µL EconoTaq (Lucigen corporation), 1 µL combined 10 µM
primers, and 12.5 µL water. Initial denaturation for 3 min at 95 °C was followed by
3 min annealing at 58 °C followed by 35 cycles of 10 s at 96 °C and 2min at 72 °C,
and a post-cycle extension at 72 °C for 7 min. Amplicons were confirmed on 1.2%
agarose electrophoresis gel prior to cleanup wth Wizard SV Gel and PCR system
(Promega). Big Dye sequencing reaction was then performed followed by a sec-
ondary clean-up prior to submission to UW Biotech for analysis (University of
Wisconsin-Madison). 16S sequences were searched with blastn against a database
of representative genomes from each clade in the Streptomyces phylogeny (see
Genome sequencing and Core-genome phylogeny below). Hits with the best bit-
score were assigned to that clade. Within clade hits 16S were then aligned with
MAFFT v7.24549 and treed with FastTree250 under the GTR substitution model.
Inhibition bioassays and scoring. Isolates were inoculated along the center of
wells. Each well contained 3 mL of yeast peptone mannitol (YPM) agar (2 g yeast
extract, 2 g peptone, 4 g mannitol, 15 g agar, 1 L H2O). Actinobacteria were incu-
bated at 28 °C for 5 d prior to the addition of the test pathogens. For fungal
pathogens, spore stocks of each fungal strain were diluted 1:10 (Supplementary
Data 3). For bacterial and yeast pathogens 3 mL of broth containing the micro-
organism was inoculated into sterile 14 mL tubes with Luria-Bertani (LB) or yeast
peptone dextrose (YPD), respectively. Cultures were shaken overnight at 28 °C and
diluted 1:10 (Supplementary Data 3). Diluted cultures were used to inoculate 3 µL
in the center of the well and the non-pathogen controls. Plates were maintained
at 28 °C for 7 d. Inhibition was scored in binary, as 0 (no inhibition) or 1 (inhi-
bition). For a subset of isolates, experimental wells were assigned a rating from
0 to 3 depending on the level of inhibition (0—no inhibition, 1—slight inhibition,
2—presence of a zone of inhibition, 3—complete inhibition).
Inhibition fraction was determined by taking the average inhibition of Strain
X vs. Pathogen Y to account for variance if multiple X by Y challenges were run.
This was done for all pathogens against X. Gram-positive, gram-negative, and
fungal averages were then computed to find the inhibition fraction for X. Strains
were grouped by source and p-values were calculated by T-test with Benjamini/
Yekutieli correction51. Fuzzy clustering was used to group inhibitory profiles using
Mfuzz52.
Genome sequencing and assembly. 120 strains were selected for whole genome
sequencing based on 16S rRNA gene sequence so to span the Streptomyces phy-
logeny, including outgroups. Cultures were grown in rich medium supplemented
with 0.5% glycine and cells were harvested by centrifugation. Cells were washed
with 10.3% sucrose, resuspended in lysozyme solution (3 mgmL−1 lysozyme,
Sigma, in 0.3 M sucrose, 25 mM Tris pH 8, 25 mM EDTA pH 8), and incubated at
37 °C for 30 min. Proteinase K (Thermo Fisher; 20 mgmL−1) was added before
incubation for 15 min at 42 °C. Cells were lysed by adding 2% SDS and rocking for
5 min until lysis was complete. Neutral phenol and chloroform were added, and
tubes were gently shaken until uniformly white. After centrifugation, the top layer
was transferred to 3M sodium acetate pH 6 and isopropanol. Tubes were gently
mixed until DNA appeared. DNA was pelleted, supernatant was removed, and the
pellet was resuspended in TE with 0.2 mg mL−1 RNaseA. Tubes were incubated
15 min at 28 °C before adding 5M NaCl and CTAB/NaCl solution. Tubes were
incubated for 10 min at 55 °C and cooled to 28 °C. CHCl3 was added, tubes were
gently shaken, and spun for 10 min at 28 °C. The top layer was transferred to a new
tube and extracted again with phenol and chloroform, followed by extraction with
chloroform and precipitation with 3M sodium acetate pH 6 and isopropanol. The
pellet was washed in 70% ethanol and resuspended in water. DNA was quantified,
checked for purity, and run on a gel to verify high molecular weight. Genomic
DNA libraries for Illumina MiSeq 2 × 300 bp paired-end sequencing were prepared
by the University of Wisconsin-Madison Biotechnology Center (TruSeq). Reads
were corrected with MUSKET v1.153, paired-ends were merged with FLASH
v1.2.754, and assembled with SPAdes v3.11.055.
Core-genome phylogeny. A genome-based, multilocus phylogeny was generated
using 93 TIGRFAM proteins in the core bacterial protein set (GenProp0799; http://
www.jcvi.org/cgi-bin/genome-properties/GenomePropDefinition.cgi?
prop_acc=GenProp0799). Genes were called with prodigal v2.6.056 and Gen-
Prop0799 profile Hidden Markov Models were used to search each genome.
HMMER v3.1b257 was used to identify protein sequences for each protein family.
Each family was then aligned using MAFFT v7.24549. Alignments were then
converted to codon alignments and concatenated. The multi-locus phylogeny was
generated using RAxML v8.1.2458 under the GTRgamma substitution model with
100 rapid bootstraps.
Analysis of biosynthetic gene clusters. BGCs were identified within each gen-
ome with antiSMASH v4.035. BGCs were determined to be full-length if 0.5 kb of
flanking sequence existed between cluster boundaries and the end of the contig.
BGCs were used to identify BGC groups via BiG-SCAPE (https://git.wageningenur.
nl/medema-group/BiG-SCAPE/) under --hybrid and --mode glocal settings at a
distance cutoff of 0.5. BGCs from our dataset were combined with all available
BGCs from MIBiG v1.359 and again groups were called in BiG-SCAPE. Distances
<0.5 were called similar, between 0.5 and 0.75 divergent, and over 0.75 unchar-
acterized. Shannon entropy with respect to phylogeny, strain source (e.g., insect-
associated, soil, plant), and insect-host order were calculated for BGC groups.
Untargeted LC/MS. Streptomyces were cultured on YPM agar media and grown
for up to 14 days or until sporulation. Two 8mm diameter cores were sampled
directly and extracted with 2 mL of MeOH for 30 min. Extracts were transferred to
new vials and vacuum dried. Extracts were dissolved in 100 μL of MeOH, followed
by 1 mL of Milli-Q water. Solid phase extraction (SPE) was conducted using
Biotage: EVOLUTE ABN (25 mg, 1 mL). Samples were loaded following con-
ditioning with MeOH and then Milli-Q water. Extracts were washed with Milli-Q
water to remove media components and primary metabolites and then eluted with
MeOH into LC/MS certified vials. Mass spectra were collected using a Bruker
MaXis ESI-Q-TOF mass spectrometer. Liquid chromatography was conducted
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using a Waters Acquity UPLC on a RP-C18 column (Phenomenex Kinetex 2.6 μm,
2.1 mm × 100 mm). Both instruments were operated using Bruker Hystar software.
A linear MeOH/H2O (0.1% formic acid) gradient was used beginning at 10%/90%
and reaching 97%/3% in 12 min and held for 3.5 min. The column was set to initial
conditions in 0.5 min and re-equilibrated for 3.5 min before subsequent runs. The
flow rate was 0.3 mLmin−1. Full-scan mass spectra (m/z 150–1550) was collected
in positive ESI mode. The following parameters were used: capillary, 4500 V;
nebulizer, 1.2 bar; dry gas flow rate, 8.0 L min−1; dry gas temperature, 205 °C; scan
rate, 2 Hz. Automatic internal calibration was conducted after each run by intro-
ducing Tune Mix (Agilent, ESI-L low concentration) through a divert valve during
re-equilibration. Bucket tables from LC/MS were generated in Bruker Profile
Analysis 2.1 with Molecular features identified as follows: S/N threshold, 5; cor-
relation coefficient threshold, 0.7; minimum compound length, 10 spectra;
smoothing width, 1; bucketing basis, M+H. Buckets were generated from LC/MS
traces between 120 and 840 s and for m/z ratios between 150 and 1500. Advanced
bucketing was used with ΔRT= 20 s and Δm/z= 20 mDa. Buckets were normal-
ized to the sum of buckets values in the analysis. Mass to charge ratios were
manually cross-referenced with Antibase37 within 5 parts per million of M, M+H,
and M+Na adduct states.
Hemolysis assay. Assays were performed in 384-well plates using sheep blood
(0.1% triton as the positive control). Sheep’s blood (Ward’s Science) was washed
with PBS and diluted to a concentration of 6 × 107 red blood cells per mL. A
volume of 50 µL of blood was incubated with compound for 1 h, and subsequently
pelleted at 4000 rpm for 10 min. Thirty microliters of supernatant were transferred
to a clear plate and OD570 was read. An increase in OD indicated the red blood
cell lysis and hemolytic activity.
Mouse studies. All mouse experiments and protocols received ethical approval
from the University of Wisconsin Institutional Animal Care and Use Committee.
Candida model. Six-week-old, specific-pathogen-free, female ICR/Swiss mice
weighing 23–27 g were used for all studies (Harlan Sprague-Dawley, Indianapolis,
IN). Animals were maintained in accordance with the criteria of the Association for
Assessment and Accreditation of Laboratory Animal Care. All animal studies were
approved by the Animal Research Committee of the William S. Middleton
Memorial Veterans Hospital. Mice were rendered neutropenic (neutrophils, 100
per mm3) by injection with cyclophosphamide (Mead Johnson Pharmaceuticals,
Evansville, IN) subcutaneously 4 days (150 mg kg−1) and 1 day (100 mg kg−1)
before infection and 2 days after infection (100 mg kg−1). Previous studies have
shown neutropenia (neutrophils, 100 per mm3) in this model for the 96-h study
period42. Organisms were subcultured on SDA 24 h prior to infection. Inoculum
was prepared by placing three to five colonies into 5 mL of sterile pyrogen-free
0.9% saline warmed to 35 °C. The final inoculum was adjusted to a 0.6 transmit-
tance at 530 nm. Fungal counts of the inoculum determined by viable counts of C.
albicans on SDA were 6.29 ± 0.03, 6.15 ± 0.10, and 6.30 ± 0.07 log10 CFUmL−1,
respectively. Disseminated infection with the Candida was achieved by injection of
0.1 mL of inoculum via the lateral tail vein 2 h prior to the start of drug therapy.
Treatment period was 8 h. Animals were sacrificed by CO2 asphyxiation. Kidneys
of each mouse were removed and placed in sterile 0.9% saline at 4 °C. The
homogenate was serially diluted and aliquots were plated on SDA for viable fungal
colony counts after incubation for 24 h at 35 °C. The lower limit of detection was
100 CFUmL−1. Results were expressed as the mean number of CFU per kidney for
three mice. No-treatment and zero-hour controls were included in all experiments.
Mouse bacterial thigh infection model. Animals for the present studies were
maintained in accordance with the criteria of the Association for Assessment and
Accreditation of Laboratory Animal Care. All animal studies were approved by the
Animal Research Committee of the William S. Middleton Memorial VA Hospital.
Six-week-old, specific-pathogen-free, female ICR/Swiss mice weighing 23–27 g
were used for all studies (Harlan Sprague-Dawley, Indianapolis, IN). Mice were
rendered neutropenic (neutrophil count, <100 mm−3) by injecting them with
cyclophosphamide (Mead Johnson Pharmaceuticals, Evansville, IN)
subcutaneously 4 days (150 mg kg−1) and 1 day (100 mg kg−1) before thigh
infection. Previous studies have shown that this regimen produces neutropenia in
this model for 5 days40. Broth cultures of freshly plated bacteria were grown
overnight to logarithmic phase to an absorbance at 580 nm of 0.3 (Spectronic 88;
Bausch and Lomb, Rochester, NY). After 1:10 dilution into fresh Mueller–Hinton
broth, the bacterial counts of the inoculum ranged from 107.0 to 107.4 CFUmL−1.
Thigh infections with each of the isolates were produced by injection of 0.1 mL of
inoculum into the thighs of isoflurane-anesthetized mice. Antibacterial therapy was
initiated 2 h after the infection procedure. After 8 h, the animals were euthanized,
and the thighs were aseptically removed, homogenized, and plated for
determination of the number of CFU. No-treatment controls were included in all
experiments.
In vivo murine studies. To analyze fractions as candidates for in vivo study, we
used Core-shell technology UPLC columns which provide extensive sensitivity and
dynamic range for small molecules60 (Fig. 5a). The threshold in terms of accuracy
was set at 3–5 ppm, well beyond the RMSD accuracy of a Bruker MaXis 4G
(specifications of better than 1 PPM). Additionally, NMR data for each fraction
were acquired using a 1.7 mm cryoprobe, the most sensitive NMR system for 1 H
analysis. Prior to in vivo testing, samples were analyzed by NMR and LCMS to
ensure characteristics of each sample matched to the original sample that exhibited
in vitro activity. Since ELSD data were used to quantify each fraction, we were able
to account for the mass of fraction during preparation of the LCMS sample.
Acquisitions were performed such that ion counts of 106 or greater were observed
for the highest abundance ions, which facilitated detection of minor components.
While there is a possibility of a known compound that does not ionize by ESI,
studies indicate that 93% of microbial natural products ionize by positive ESI61.
LCT-ToF was used (as in Nielsen et al.61 where 93% ionization of microbial
natural products was reported). In addition, a Bruker MaXis 4G with an Acquity
UPLC front end and core shell columns was used to maximize sensitivity for ESI-
MS of small molecules (dynamic range of 4.7 orders of magnitude). As such, ion
counts in the millions maintain accuracy and appropriate peak shape. Low
abundance ions (below 100 counts) can also be detected (noise is ~30–50 counts).
Thus, with the increased accuracy and range of our instrument, the 93% estimate of
microbial natural products from Nielsen et al. is a lower bound. Some lipids (e.g.,
those without carboxylic acid groups) and terpenes (e.g., those with few oxygens)
ionize poorly and may be missed by ESI-MS, but within actinomycetes, we
encounter few terpenes being produced under laboratory conditions.
Mice were treated 2 h after infection and sampled 6–8 h after treatment.
Bacteria were grown in three different media (A media, ISP-2, YPM, and A-
Medium; 100 mL each) with Diaion HP20 (7% by weight) and shaken at 200 rpm
at 28 °C for 7 days. Filtered HP20 was washed with water and extracted with
acetone. The acetone extracts from the three media were combined and followed by
solid phase extraction using ENV+ columns to generate four fractions. These four
fractions were further purified by HPLC to generate 80 fractions for each strain in a
96-well plate. High-throughput screening was used to evaluate the antimicrobial
activity of these fractions. Dereplication based on 1.7 mm NMR and HRMS was
used to select promising hits. Select strains were re-grown in the large scale in the
three media, and followed the same processor mentioned before to generate the
fractions containing potential novel active compounds. These fractions were
formulated and tested in vivo activity (Fig. 5a).
In vitro MIC susceptibility testing. MICs of cyphomycin for the Candida isolates
were determined using a broth microdilution method in accordance with the
guidelines presented in Clinical and Laboratory Standards Institute (CLSI) docu-
ment M27-A3 for Candida and M38-A2 for Aspergillus40,42. MIC values of
cyphomycin were defined as the lowest concentration at which a prominent
decrease in growth turbidity (i.e., 50% reduction in growth determined spectro-
photometrically) relative to the turbidity of the compound-free control at 600 nm
was observed. Median MIC from replicate assays is reported.
Cyphomycin—culturing and isolation. Streptomyces ISID311 was grown in A-
medium broth (20 g soluble starch, 10 g glucose, 5 g peptone, 5 g yeast extract, 5 g
CaCO3 per liter) using Fernbach flasks [5× (1 L of medium in 2.8 L+ 70 g of
HP20)] and shaken for 7 days at 28 °C and 200 rpm. The HP20 was filtered and
washed with distillated water and soaked with acetone. Organic solvent was fil-
tered, vacuum dried, and partitioned with ethyl acetate/water. Organic phase was
separated and dried to give the crude extract (2.3044 g). Extract was purified by
SPE-C18 (55 µm, 20 g) using the following gradient: 200 mL (20% MeOH-H2O,
A1: 72.8 mg); 200 mL (40% MeOH-H2O, A2: 152.5 mg); 200 mL (60% MeOH-
H2O, A3: 132.3 mg); and 200 mL (100% MeOH, A4: 1.9349 g).
A4 was purified by semi-preparative HPLC using C18 semipreparative column
(Phenomenex Luna, C18(2), 5 µm, 250 × 10 mm) and the following gradient of
MeOH and H2O (containing 0.1% of acetic acid) at 4 mLmin−1: min 1–20 (linear
gradient from 80% MeOH-H2O to 100% MeOH); min 20–22 (isocratic flow of
100% MeOH); min 22–22.5 (linear gradient from 100% MeOH to 80% MeOH-
H2O); and min 22.5–27.5 (isocratic flow of 80% MeOH-H2O) to yield cyphomycin
(89.0 mg, tR= 11.4 min).
Cyphomycin—structural determination. The molecular formula of cyphomycin
was C77H122O26 based on positive ion HRESIMS ([M+H]+ m/z 1463.8282, err 1.0
ppm). The 1H and 13C NMR spectral data of 2 are shown in Supplementary
Figure 3AI. The 13C NMR spectrum showed 77 signals assigned to 12 methyl, 18
methylene, 36 methine, 5 carbonyl carbons, 4 tertiary carbons sp2 and 2 quaternary
carbon groups by multiplicity-edited gHSQC experiment. The COSY and HSQC-
TOCSY spectra revealed connectivity from H-2 to H-15 and H-18 to H-43
(Supplementary Figure 3AF).
Connection of these two spin systems was revealed with the HMBC correlation
of H-18 (δH 2.09 and 1.33) to C-16 and C-17; H-15 (δH 4.69) to C-16; and H-35
(δH 5.14) to C-1. Geometry of the two double bonds of macrolide were determine
to be E configured by coupling constants of 3JH-2,H-3 (15.8 Hz) and 3JH-32,H-33 (15.6
Hz). The positions of methine groups H-4, H-14, H-34, H-36, H-38 and H-40 were
assigned by 1H-1H COSY correlations to methyl groups H-44, H-45, H-46, H-47,
H-48 and H-49, respectively. The methyl group H-43 was assigned as terminal
group of side chain by its triplet multiplicity in 1H NMR spectrum and HMBC
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correlations to C-41 and C-42. Positions of oxygenated methine and methylene
groups in macrolactone moiety were established by HMBC, COSY and HSQC-
TOCSY correlations, and comparison of NMR data of compounds PM100117/838.
Difference in macrolactone moiety of compound 1 versus PM100117/8 is the
additional methyl group H-44 attached to C-4. Other similar macrolactones of 36
members are described in GT-35 and Deplelides A and B39.
The presence of two sugar units was evidenced by signal of 1H and 13C NMR of
two anomeric protons and carbons at δH 5.01 (H-1´) and δH 4.58 (H-1´´); and δC
96.4 (C-1´) and δC 104.0 (C-1´´), respectively. The first was established as α-
axenose by HMBC, COSY, ROE correlations and NMR data comparison with
literature38 (Supplementary Figure 3AG).
There are two 1H spin systems from H-1´ to H-2´ and from H-4´ to H-6´; and
HMBC correlations from methyl H-7´ to C-2´, C-3´ and C4´. Connection of this
sugar to side chain of macrolactone was observed with HMBC correlations of H-1´
to C-41. Small coupling constant of H-1´ and H-4´suggested they should be in
equatorial orientation. ROE correlation of H-41 to H-5´ supported axial
orientation of H-5´.
The second sugar was established as β-amicetose. It was constructed by the 1H
spin system from H-1´´ to H-6´´. Large coupling constants 3JH-1´´,H-2´´ax (7.6 Hz)
and 3JH-4´´,H-5´´ (9.3 Hz); and ROE correlation between H-1´´ and H-5´´ suggested
axial orientation of H-1´´, H-4´´ and H-5´´. Connection of both sugars was
observed by the HMBC correlation of H-1´´ to C-4´. The HMBC correlation of H-
4´´ to C-50 connected the β-amicetose with the ester carbonyl group of
naphthoquinone derivative moiety. 1H NMR signals for H-54 (δH 8.01), H-61 (δH
8.07) and H-62 (δH 7.79); 1H-1H coupling constants 3JH-54,H-62 (1.3 Hz) and 3JH-61,
H-62 (8.0 Hz); and 1H-1H COSY correlations between H-54/H-62 and H-61/H-62
indicated the presence of an aromatic ring trisubstituted moiety. HMBC
correlations of H-54 to C-56; H-61 to C-55 and C-59; H-62 to C-60; H-57 to C-55,
C-59 and C-64; and H-64 to C-57, C-58, and C-59 indicated the presence of a
quinone moiety methylated in C-58 and connected to the aromatic ring. HMBC
correlation of H-63 to C-50, C-51 and C-52; H-52 to C-50 and C-53; H-54 and H-
62 to C-52; evidence the connection of C-50, C-51, C-52, C-53 and C-63 to
aromatic ring of naphthoquinone moiety. Compound 2 was named cyphomycin.
Data availability
Genomic data can be found at DOI: 10.5281/zenodo.2436565. All other data are
available in the main text or the supplementary materials; Permits for collections
and accessing genetic resources in Brazil were issued by SISBIO #46555–5 and
CNPq #010936/2014–9. Costa Rican collecting permits were issued by the Comi-
sión Institucional de Biodiversidad (Institutional Biodiversity Committee, Uni-
versity of Costa Rica; Resolutions # 012 and 020; Material Transfer Agreement
MTA VI-4307–2013) and authorized by La Selva Biological Station and Las Brisas
Nature Reserve. A modified version of the southern pine beetle (Fig. 1) photo from
Erich G. Vallery is used under the Creative Commons Attribution 3.0 License.
Photos of Cyphomyrmex (Figs. 1 and 5) are used under a perpetual commercial
license from Alexander Wild.
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